• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Christian John Lillis on C diff, Public Health, and the Role of Pharmacists

by MM360 Staff | May 24, 2025 | Myeloma News

Source: Pharmacy Times articles Christian John Lillis reflects on key insights from the 2025 Peggy Lillis Foundation C diff Summit, highlighting the critical role of pharmacists in infectious disease care, persistent challenges in patient outcomes, and the need for...

Market Access: A Unique Career Path for Pharmacists

by MM360 Staff | May 24, 2025 | Myeloma News

Source: Pharmacy Times articles Market access offers pharmacists a dynamic career path. Read More

Real world outcomes with elotuzumab-based therapies for patients with relapsed refractory multiple myeloma: a Mayo Clinic experience

by MM360 Staff | May 24, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Physical Activity Can Improve Quality of Life in Patients With Newly Diagnosed Multiple Myeloma

by MM360 Staff | May 23, 2025 | Myeloma News

Source: Pharmacy Times articles Physical activity significantly enhanced quality of life and reduced fatigue and depression in patients with newly diagnosed multiple myeloma. Read More

Oral GLP-1 Agonist Orforglipron Shows Promise for Type 2 Diabetes and Weight Management

by MM360 Staff | May 23, 2025 | Myeloma News

Source: Pharmacy Times articles Orforglipron showed promising results in managing type 2 diabetes, offering a potential oral alternative to injectable treatments. Read More

Promising Early Results for Linvoseltamab Combinations in Relapsed/Refractory Multiple Myeloma

by MM360 Staff | May 23, 2025 | Featured News, Myeloma News

Regeneron Pharmaceuticals has announced promising initial results from its Phase 1b LINKER-MM2 trial, evaluating linvoseltamab in combination with proteasome inhibitors carfilzomib or bortezomib for patients with relapsed/refractory multiple myeloma (R/R MM). These...
« Older Entries
Next Entries »

Recent Content

  • Glioma trial of intranasal therapy NEO100 fills all patient slots
  • WHO grants nonproprietary name to ovarian cancer cell therapy
  • Putative multiple myeloma susceptibility genes identified by exome sequencing of 347 familial and early-onset cases
  • Carvykti label updated to include survival benefit data in myeloma
  • Addition of daratumumab to standard triplet regimens achieved better survival in newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
  • Inflammatory markers from routine blood tests predict survival in multiple myeloma: a Systematic Review and meta-analysis
  • FDA approves ziftomenib to treat some relapsed leukemia patients
  • (no title)
  • The challenge of non-transplant eligible, newly diagnosed multiple myeloma
  • Camera pill to find pancreatic cancer seeks breakthrough status
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT